Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.61 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.57 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPA3 | P15088 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL19285616 | 1.00 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL30336931 | 1.00 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL21158800 | 1.00 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL19285614 | 1.00 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1005247 | 1.00 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL30083110 | 1.00 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1030966 | 0.98 | SLC6A2 (0.63) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Levamfetamine SCHEMBL4596702 | 0.98 | SLC6A2 (0.63) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL3681578 | 0.98 | SLC6A2 (0.63) | SLC6A2TAAR1SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1030967 | 0.98 | SLC6A2 (0.63) | SLC6A2TAAR1SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027043-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | TRIS PHARMA INC (US) | 2026-01-29 | — | — | US | claimed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | claimed |
| EP-3638211-B1 | DELAYED SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | SpecGx LLC (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | claimed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | claimed |
| US-20230105795-A1 | COMBINATION DRUG THERAPIES FOR CNS DISORDERS | JAVED MOHAMMAD (US) | 2023-04-06 | — | — | US | claimed |
| EP-4096508-A1 | COMBINATION DRUG THERAPIES FOR CNS DISORDERS | Javed, Mohammad (US) | 2022-12-07 | — | — | EP | claimed |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | PHARMAPOTHECA, LLC (US) | 2021-09-21 | — | — | US | claimed |
| WO-2021154631-A1 | COMBINATION DRUG THERAPIES FOR CNS DISORDERS | JAVED MOHAMMAD (US) | 2021-08-05 | — | — | WO | claimed |
| EP-2023900-A1 | CONTROLLED DOSE DRUG DELIVERY SYSTEM | Shire LLC (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007133203-A1 | CONTROLLED DOSE DRUG DELIVERY SYSTEM | SHIRE LLC (US) | 2007-11-22 | — | — | WO | claimed |
| US-20070264323-A1 | CONTROLLED DOSE DRUG DELIVERY SYSTEM | SHIRE LLC (US) | 2007-11-15 | — | — | US | claimed |
| US-20060204575-A1 | Amphetamine formulations | ACTAVIS GROUP PTC EHF | 2006-09-14 | — | — | US | claimed |
| US-20050158384-A1 | Sustained release delivery of amphetamine salts | SHIRE LLC | 2005-07-21 | — | — | US | claimed |
| EP-1542660-A1 | SUSTAINED RELEASED DELIVERY OF AMPHETAMINE SALTS | Shire Laboratories Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2005044238-A1 | MODIFIED RELEASE SOLID DOSAGE FORM OF AMPHETAMINE SALTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-05-19 | — | — | WO | claimed |
| WO-2004028509-A1 | SUSTAINED RELEASED DELIVERY OF AMPHETAMINE SALTS | SHIRE LABORATORIES, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040059002-A1 | Sustained release delivery of amphetamine salts | SHIRE LABORATORIES, INC. | 2004-03-25 | — | — | US | claimed |
| US-6605300-B1 | For treatment of ADHD | SHIRE LABORATORIES, INC. | 2003-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544385-B2 | Combination drug therapies for CNS disorders | SLC6A3, SLC6A2, SLC18A2 | SLC6A2 2/4885SLC6A3 1/4885TAAR1 63/4885 |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885SLC6A3 1/4885TAAR1 52/4885 |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | SLC6A2 2/4885SLC6A3 1/4885TAAR1 51/4885 |
| US-20260027043-A1 | EXTENDED RELEASE AMPHETAMINE TABLETS | SLC6A3, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A3 1/4885TAAR1 238/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885SLC6A3 1/4885TAAR1 37/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885SLC6A3 1/4885TAAR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.